Skip to content

#生物标志物

Today 0 items
Sep 22Tue
  1. Nature Medicine50

    Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study

    The PATHFINDER 2 study evaluated the safety and performance of a blood-based multi-cancer early detection test in an intended-use population of more than 35,000 participants aged 50 years or older. It reports outcomes on how the test performs when used prospectively in people without a prior cancer diagnosis. The findings add interventional evidence on safety and performance in the intended-use setting.

    Why it matters: Large interventional evidence on a multi-cancer early detection blood test in its intended-use population.

  2. Nature Medicine52

    Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial

    Secondary endpoint analyses from the NHS-Galleri randomized controlled trial characterize how a blood-based multi-cancer early detection test performed when added to usual care in more than 142,000 participants without suspicion of cancer. The trial evaluated the test's performance as a screening tool in a general population, offering data on its behavior outside diagnostic settings.

    Why it matters: Reports performance data for a multi-cancer early detection blood test in a randomized trial of over 142,000 people.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org